Cocrystal Pharma Inc expected to post a loss of 60 cents a share - Earnings Preview

Cocrystal Pharma

25/03/2024 12:33

* Cocrystal Pharma Inc  COCP.OQ   COCP.O  is expected
to show no
change in quarterly revenue when it reports  results on March 27
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Cocrystal Pharma Inc is
for a
loss of 60 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cocrystal
Pharma
Inc is $10.00​, above​ its last closing price of $1.53. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.50       -0.53      -0.41     Beat    22.6
 Jun. 30 2023  -0.53       -0.58      -0.41     Beat    29.3
 Mar. 31 2023  -0.59       -0.67      -0.64     Beat    5.2​
 Dec. 31 2022  -0.72       -0.73      -0.55     Beat    24.3
 ​​Sep.        -0.48       -0.48      -0.70     Missed  -45.8
 30 2022                                                
 Jun. 30 2022  -0.54       -0.52      -3.00     Missed  -477​
 Mar. 31 2022  -0.36       -0.42      -0.48     Missed  -14.3
 Dec. 31 2021  -0.48       -0.48      -0.48     Met     0
 This summary was machine generated March 25 at 12:33 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)